Celularity

08/27/2026

RELEASE: Celularity is proud to announce a U.S. manufacturing collaboration with MuseCell Innovations® to support the Dezawa MuseCell® platform at our Florham Park, New Jersey facility.

This collaboration reflects Celularity’s deep expertise in cellular medicine and advanced manufacturing and represents an exciting opportunity to support the continued advancement of innovative cellular technologies.

Read the announcement: https://www.businesswire.com/news/home/20260827982573/en/Celularity-and-MuseCell-Innovations-Announce-U.S.-Manufacturing-Collaboration-for-the-Dezawa-MuseCell-Platform

Celularity Inc. and MuseCell Innovations announce U.S. manufacturing partnership for production of Dezawa MuseCells in Florham Park, NJ facility.

06/04/2026

RELEASE: Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

This milestone marks the establishment of one of the first state-level frameworks in the United States enabling the physician-directed use of allogeneic cellular therapies outside of traditional federal approval pathways, creating a potential model for broader market expansion.

Read the full release here:
https://www.globenewswire.com/news-release/2026/06/04/3306696/0/en/celularity-and-fountain-life-announce-availability-of-cenplacel-l-for-investigational-use-under-new-florida-law-establishing-scalable-pathway-for-advancement-of-placental-derived-c.html

03/10/2026

RELEASE: Celularity has entered into a strategic commercialization partnership for its placental-derived biomaterials portfolio, a transaction expected to generate up to $35 million in upfront and milestone payments while strengthening the company’s capital position.

Importantly, Celularity will retain exclusive manufacturing rights at its FDA-compliant facility in New Jersey, preserving long-term revenue potential while sharpening focus on advancing its longevity-focused therapeutic pipeline. This move reflects a disciplined strategy to streamline operations, reduce expenses, and concentrate resources on developing placental-derived cellular therapies targeting the fundamental drivers of aging.

Read the full press release below:
https://www.globenewswire.com/news-release/2026/03/10/3252827/0/en/Celularity-Secures-35-Million-Strategic-License-Deal-Strengthens-Capital-Position-to-Advance-Longevity-Focused-Strategy.html

02/10/2026

RELEASE: Celularity Inc. (Nasdaq: CELU) Receives $12.2 Million from Sale of New Jersey Net Operating Losses

"The funds support disciplined capital allocation to commercial opportunities for our GMP-level stem cell and other cell therapies and regenerative medicine programs, all targeting longevity and the preservation of human performance,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer.

Read the full release here:
https://www.globenewswire.com/news-release/2026/02/10/3235309/0/en/Celularity-Receives-12-2-Million-from-Sale-of-New-Jersey-Net-Operating-Losses.html

12/26/2025

RELEASE: Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz.

Biovance® has been supported by a highly efficient, proven scalable manufacturing process since its commercial launch in April 2014, which today allows us to operate comfortably under the new Medicare reimbursement for skin substitute products.

Read the full release here:
https://www.globenewswire.com/news-release/2025/12/26/3210532/0/en/Celularity-CEO-Comments-on-Centers-for-Medicare-Medicaid-Services-Withdrawal-of-Skin-Substitute-Local-Coverage-Determinations.html

12/22/2025

RELEASE: Celularity announces the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.

This closing strengthens Celularity’s financial position and provides meaningful flexibility as we continue to analyze and prioritize our platform and pipeline.

Read the full release here:

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company...

12/18/2025

RELEASE: Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

Celularity has entered into two binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.

READ THE FULL RELEASE HERE:
https://www.globenewswire.com/news-release/2025/12/18/3208116/0/en/Celularity-Reaches-Binding-Term-Sheets-on-Financing-Transactions-to-Support-Its-Strategic-Vision.html

10/30/2025

Big announcement! We are excited to be part of DefEYE’s focused expansion into the ophthalmic space and to demonstrate the transformative power of placental-derived regenerative biologic solutions. This strategy fits into our objective of accessing new markets for our portfolio of commercial products.

Read the full release here:
https://www.globenewswire.com/news-release/2025/10/30/3177365/0/en/Celularity-and-DefEYE-Inc-Partner-to-Advance-Growth-of-Regenerative-Therapies-in-Eye-Care.html

10/14/2025

Exciting news! Phase 2 clinical trial results published on the safety and efficacy of placenta-derived cells for diabetic foot ulcers complicated by Peripheral Artery Disease.

This is a significant milestone for Celularity, and importantly, for patients battling diabetic foot ulcers complicated by peripheral artery disease, which is a patient population with a critical unmet medical need and limited treatment options.

Read the full release here:

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with...

09/03/2025

We are pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025. This comes on the heels of the recently announced retirement of all $32.0 million of the Company’s senior secured debt plus $9.6 million in associated unpaid interest.

Read the full release here:

Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord...